에 대한 최신 뉴스 Ingevity (NYSE:NGVT) 주식

Ingevity

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

benzinga_deal_dispatch2

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Ingevity Corp

Counterpoint Research has cut growth expectations for <a href="https://www.benzinga.com/topic/smartphones" target="_blank" rel="noreferrer noopener">global smartphone shipments</a> in 2025 to 1.9% on Wednesday, down from 4.2% previously, citing Trump administration tariff-related uncertainties.
The firm also revised shipment growth from China down to near flat and expects Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)&nbsp;shipments to slow as the companies pass the <a target="_blank" href="https://www.counterpointresearch.com/report/market-monitor-smartphone-brand-shipment-analysis-by-model-q1-2025" rel="noreferrer noopener">cost burden on</a> consumers.
President Trump announced a series of tariffs on its trading partners on April 2 to encourage manufacturing in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth" rel="noreferrer noopener">Apple Tops Global Smartphone Sales With 19% Share, Boosted By iPhone 16e, Emerging Market Growth</a>
On May 12, Beijing and Washington&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" rel="noreferrer noopener">agreed to lower&nbsp;tariffs</a> on each other's products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China's 125% duties on U.S. goods will drop to 10% for 90 days.
Last week, International Data Corporation (IDC) in its research report cut the 2025 <a href="https://www.benzinga.com/news/25/05/45708416/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">global smartphone shipment</a> growth outlook to 0.6% from 2.3%.
IDC expects China smartphone shipments to grow by 3% in 2025, driven by government subsidies.
In contrast,&nbsp;Apple&nbsp;is forecast to decline 1.9% in 2025 due to ongoing competition from&nbsp;Huawei, the overall economic slowdown, and the lack of subsidies for most of its models.
IDC expects the U.S. smartphone shipment to grow 1.9% in 2025, down from 3.3% in 2017, due to increased uncertainty and tariff-related price increases.
Meanwhile, Deepwater Research&#8217;s Gene Munster estimated that Apple has <a href="https://www.benzinga.com/markets/tech/25/06/45764870/apple-has-at-least-two-years-before-losing-customers-despite-its-several-ai-missteps-says-gene-munster-heres-why" target="_blank" rel="noreferrer noopener">about two years</a> to perfect its AI strategy, but it will require increased investments.
The AI features of smartphones are the<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44613270/apple-set-for-strong-iphone-upgrade-cycle-driven-by-ai-analyst-says" rel="noreferrer noopener"> key deciding factor</a> determining their prospects.
<h2 class="wp-block-heading">Apple Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Apple have an average 1-year price target of $238.79, representing an expected upside of 17.47%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 3 analysts have bearish recommendations on Apple, while 21 analysts have bullish ratings. The street high price target from Wedbush is $325.0, while the street low from Jefferies is $167.88.
APPL&nbsp;Price Action:&nbsp;Apple stock is down 0.50% to $202.26 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image by Wongsakorn 2468 via Shutterstock

Tech

Trading Ideas

AAPL

SSNLF

Tariffs, AI And Trade War: Apple's Smartphone Growth To Take A Hit, Experts Say

WIIM

FUFU

BitFuFu shares are trading higher after the company provided monthly Bitcoin holdings and production updates for May.

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

REVG

REV Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Competitive statewide RFP win provides a platform for efficient expansion within the state
TEL AVIV, Israel, June 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has been awarded a statewide technology procurement contract by the North Carolina Sheriff's Association, emerging as the only new electronic monitoring technology provider selected through this competitive RFP. This contract serves as a procurement vehicle to allow all counties in North Carolina to contract directly with SuperCom on preset terms, most of the time without an additional RFP process. This strategic win is another testament to the Company's rapid expansion across the North American public safety market.

Contracts

SPCB

SuperCom Wins Statewide Technology Procurement Contract With North Carolina Sheriff's Association As Sole New Electronic Monitoring Provider

YEXT

Yext shares are trading higher after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

JFIN

Jiayin Group shares are trading higher after the company reported a year-over-year increase in its Q1 financial results.

Keybanc analyst Bradley Thomas reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Overweight and maintains $135 price target.

Reiteration

OLLI

Keybanc Reiterates Overweight on Ollie's Bargain Outlet, Maintains $135 Price Target

Thor Industries shares are trading higher after the company reported better-than-expected Q3 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $95 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $95 Price Target

Keybanc analyst Bradley Thomas reiterates Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sector Weight to Sector Weight.

Keybanc Reiterates Sector Weight on Dollar Generalto Sector Weight

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

LITE

Lumentum Holdings shares are trading higher after the company raised its Q4 guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.

UBS analyst Karl Keirstead upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raises the price target from $210 to $265.

Upgrades

SNOW

UBS Upgrades Snowflake to Buy, Raises Price Target to $265

ASAN

Asana shares are trading lower after the company issued FY26 guidance below estimates.

UBS analyst Anojja Shah initiates coverage on Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) with a Neutral rating and announces Price Target of $48.

Initiation

UBS Initiates Coverage On Sonoco Prods with Neutral Rating, Announces Price Target of $48

Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy
Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival ("PFS")
Clinical Benefit Rate ("CBR") was 59.4% (n=32), comprised of 18 subjects with stable disease and 1 subject with a partial response
Potential to address 13,500 new incidents of STS each year and market opportunity expected to grow to $2.6B by 20301
On-demand video webcast with members of the Moleculin management team and internationally renowned Key Opinion Leaders available Thursday, June 5th
HOUSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ("STS lung mets") (MB-107).
The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ("MTD", "RP2D" respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit <a href="https://www.globenewswire.com/Tracker?data=cIErFT_tsX39yiMPB49nWwCQtr1tUxq6RYQrO1PLLkBoMcgRmngECF7Tli-kjopu1eRuZxphaaV2VvIK4ZyejqFdWESfDHBbuhsXHq9zly4=">clinicaltrials.gov</a> and reference identifier NCT04887298.

General

MBRX

Moleculin Biotech Reports Phase 1B/2 Trial Results For Annamycin In Soft Tissue Sarcoma Lung Metastases, Showing Efficacy As 7th Line Monotherapy With 59.4% Clinical Benefit Rate, Improved Overall And Progression-Free Survival

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) is <a target="_blank" href="https://www.benzinga.com/topic/rivian" rel="noreferrer noopener">revamping the charging</a> experience for its electric vehicle customers.
The EV maker is launching a software update to its vehicles and smartphone app, offering more transparency about energy consumption and faster charging speeds, the Verge <a target="_blank" href="https://www.theverge.com/news/678005/rivian-ev-charging-software-update-battery-fast-charging" rel="noreferrer noopener">reported</a> on Tuesday.
Rivian&#8217;s Energy app will now include &#8220;Charging&#8221; for energy intake and &#8220;Energy Monitor&#8221; for energy output.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" rel="noreferrer noopener">Tesla Rival Rivian Taps AI Expert Aidan Gomez To Drive Innovation</a>
The Charging tab shows a detailed breakdown of where the energy is going, including the battery and any connected accessories.
The Energy Monitor tab contains a new chart detailing how climate, outlets, and drive systems consume energy.
A new &#8220;Trip Target&#8221; feature provides charging recommendations when using navigation for a trip involving a charging stop to notify customers when they need to charge for the rest of the journey. 
Rivian is also adding a feature to precondition the battery on demand. The company obtained faster DC charging via a software update for its first- and second-generation EVs by optimizing battery temperatures in simulation.
Wassym Bensaid, Rivian&#8217;s chief software officer, told the Verge that it will roll out a new &#8220;Smart Charging&#8221; feature in July that allows customers to time their home-charging sessions.
In 2025, Rivian will launch a new bidirectional charging feature that enables users to utilize their vehicles as mobile power generators to send power to electronic devices.
Rivian stock surged over 28% in the last 12 months despite challenges associated with public EV charging, federal spending on charging installations, and the Trump administration&#8217;s tariff policies.
Despite mounting concerns over global trade tensions and tariffs, the company <a href="https://www.benzinga.com/markets/equities/25/05/45243985/rivian-holds-firm-on-45k-r2-price-despite-tariff-pressures-ceo-rj-scaringe-says-its-important-for-us-as-ev-maker-tops-q1-estimates" target="_blank" rel="noreferrer noopener">remains committed to</a> the $45,000 starting price for the upcoming R2 electric vehicle. It expects per-unit tariff impacts of approximately $2,000 for 2025.
Price Action:&nbsp;Rivian shares are trading higher by 0.97% at $14.51 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink" target="_blank" rel="noreferrer noopener">Nio Stock Drops After Q1 Results And Outlook Disappoints The Street, Margins Shrink</a></li>
</ul>
Photo: Shutterstock

RIVN

Rivian EVs Just Got Smarter: New App Tracks Energy Use And Speeds Up Charging

Press Releases

Ingevity elects Kevin Willis to its board of directors

Ingevity announces dates for fourth-quarter and full year 2024 earnings release and webcast

Ingevity announces plans to explore strategic alternatives for Performance Chemicals Industrial Specialties product line and North Charleston CTO refinery; releases preliminary 2024 financial results

Ingevity named as one of America's Most Responsible Companies of 2025 by Newsweek

Ingevity reports fourth quarter and full year 2024 financial results

Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation

Ingevity announces appointment of David H. Li as president and CEO

Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

Ingevity announces dates for first-quarter 2025 earnings release and webcast

Ingevity reports first quarter 2025 financial results

Albemarle

Ashland

ASP Isotopes

Avient

Axalta Coating Systems Ltd. Common Shares

Axalta Coating Systems

Balchem

Celanese

DuPont de Nemours

Ecolab

Ecovyst

Eastman Chemical

Element Solutions

H.B. Fuller

International Flavors & Fragrances, Inc. Common Stock

Intl Flavors & Fragrances

Innospec

Quaker Houghton

Minerals Technologies

NewMarket

PPG Indus

Perimeter Solutions

RPM Intl

Stepan

Sherwin-Williams Company (The) Common Stock

Sherwin-Williams

Sociedad Quimica y Minera S.A. Common Stock

Sociedad Quimica Y Minera

Sensient Technologies Corporation Common Stock

Sensient Technologies

Wells Fargo

BMO Capital

Oppenheimer

Loop Capital

Jefferies

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">비폭력 마약 범죄자 석방</a>를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다.
<a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">AP 통신</a>에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">트럼프의 취임식 하루 전</a>이다.
마감일이 다가오면서, 이 앱의 운명은 소위 &#8216;틱톡을 위한 국민 입찰&#8217;에 달려 있다. 이는 &#8220;샤크 탱크&#8221;의 케빈 오리어리(Kevin O&#8217;Leary)와 억만장자 프랭크 매코트(Frank McCourt)의 지원을 받는다. 분명히 틱톡의 미국 자산은 여전히 ​​손에 넣을 수 있지만 가격표나 거래가 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">며칠 안에</a> 현실적으로 완료될 수 있는지 여부에 대해서는 아직 언급이 없습니다.
<h2 class="wp-block-heading">파산 블록</h2>
조앤(Joann Inc.)은 12개월 이내에 두 번째 파산 계획을 수립하고 있다. 오하이오 기반의 이 패브릭 및 공예 소매업체는 약 800개 매점의 포트폴리오 구매자를 찾고 있다.
고든 브라더스 리테일 파트너스(Gordon Brothers Retail Partners)가 "스톡킹 호스(stalking horse)" 입찰자로 나타났지만, 조앤은 여전히 더 나은 제안을 기대하고 있다. 아마도 바늘귀를 통과시키는 법을 아는 사람에게서 말이다.
이전에 82세의 소매업체는 사모펀드 레너드 그린 앤 파트너스(Leonard Green &amp; Partners)의 관리 하에 있었으며, 2011년 16억 달러의 레버리지 인수로 인수되었다. 이 회사는 부채에 묶여 있었고 (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">보도에 따르면</a> 2020년 10월 31일 기준 장기 부채가 9억 2,100만 달러였음) <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">2021년에 상장</a>되었다.
조앤은 <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">2024년 3월</a>에 다시 비공개로 전환되었으며, 당시 10억 달러의 총 부채를 약 5억 달러 줄이는 데 성공했다.
지난해 자구 노력이 무색해진 조앤은 최근 소매업체들의 증가하는 피해 사례에 합류하고 있다: <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">몇 가지를 예로 들면</a> 파티 시티(Party City), 빅랏츠(Big Lots), LL 플로링(LL Flooring), 더바디샵(The Body Shop) 및 더 컨테이너 스토어(The Container Store) 등이 있다.
컬크랜드 앤 앨리스(Kirkland &amp; Ellis)가 법률 문제를 처리하고 있으며, 센터뷰 파트너스(Centerview Partners LLC)가 재무 자문을 제공한다. 알바레즈 앤 마살 북미(Alvarez &amp; Marsal North America, LLC)가 구조조정 과정을 감독하고 있다.
<h2 class="wp-block-heading">신규 블록</h2>
<ul>
<li>투자 회사 KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)가 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)를 고용하여 필리핀 핀테크 회사 마야(Maya)의 지분 매각 경매를 운영하도록 했다고 로이터가 보도했다.</li>
<li>뉴욕에 본사를 둔 KKR은 마야의 20% 이상의 지분을 보유하고 있으며, 매각이 진행된다면 마야의 가치는 20억 달러를 초과할 수 있다고 한 소식통이 전했다.</li>
<li>듀폰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>)은 <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">전자 사업 분리</a>를 추진하고 있다. 델라웨어 주 윌밍턴에 본사를 둔 이 회사는 거래가 11월 1일까지 완료될 것으로 예상하고 있다. 듀폰은 전략적 대안을 평가한 후 수자원 사업을 유지하기로 결정했다.</li>
<li>인제비티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>)는 성과 화학 산업 전문 분야를 매각하고 있으며, 사우스 캐롤라이나주 노스 찰스턴 부지의 일부를 매각할 계획다. 이 회사는 이익 현금 흐름을 개선하고 검토 과정을 연말까지 마무리할 것으로 기대하고 있다. 거래 여부는 <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">아직 미정</a>이다.</li>
<li>S&amp;W 시드 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>)는 매물에 나와 있다. 이는 합병 또는 재자본화도 고려 중이며, 이는 더 큰 전략적 검토의 일환이다. 콜로라도주 롱몬트에 본사를 둔 이 회사는 호주 자회사를 이미 매각했다. 앨런 윌리츠(Alan Willits) 회장은 "우리는 주주 가치를 최적화하는 모든 이니셔티브를 지원하고 있으며, S&amp;W 시드가 향후 성공을 위해 최적의 위치에 있도록 보장하기 위해 잠재적 전략적 대안의 전체 범위를 고려할 것이다"라고 밝혔다.</li>
</ul>
참고: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">스타 비행 시험 중 폭발, 일론 머스크: ‘성공은 불확실하지만 오락은 보장된다!'</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
<ul>
<li>로렌코 곤칼베스(Lourenco Goncalves)는 월요일 기자 회견에서 주목을 받았다. <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">블룸버그</a>에 따르면, 클리브랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)의 CEO는 일본을 "악당"이라고 부르며, 중국에 해로운 관행인 덤핑과 과잉 생산을 가르쳤다고 비난했다. 그의 발언은 클리브랜드 클리프스가 U.S. 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 새로운 입찰을 노리고 있는 가운데 나왔으며, 바이든이 일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>)의 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$140억 인수 시도</a>를 차단하기로 결정한 후이다. 자신의 회사를 잠재적 구매자로 포지셔닝하면서 곤칼베스의 수사는 철강 산업의 긴장을 고조시켰다. 일본제철은 이제 트럼프에게 <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">거래 성사를 도와달라고 요청</a>하고 있다.</li>
<li>T-모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)은 비스타 미디어(Vistar Media)를 6억 달러에 인수할 것이다. 이 통신 회사는 이 거래가 광고 사업을 강화할 것으로 기대하고 있다고 로이터가 보도했다.</li>
</ul>
지난주 생명공학 및 제약 부문 거래가 잇따랐다. 다음은 벤징가의 보도 샘플이다:
<ul>
<li>바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)은 세이지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)의 모든 미상환 주식을 <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">주당 7.22달러에 인수하겠다는</a> 비공식 제안을 제출했다. 골드만삭스 애널리스트인 살빈 리히터(Salveen Richter)는 이 제안이 출산 후 우울증(PPD) 치료제인 주르주배(Zurzuvae) 런칭의 재무적 성공을 고려할 때 전략적으로 타당하다고 믿고 있다.</li>
<li>GSK plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">IDRx, Inc., 위장관 간질성 종양(GIST)을 위한 정밀 치료제에 초점을 맞춘 생명공학 회사</a>를 10억 달러에 인수하기로 합의했다. 이 거래는 특정 규제 승인 이정표 후 GSK가 추가로 1억 5천만 달러를 지불해야 할 수도 있다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 스콜피온 테라퓨틱스(Scorpion Therapeutics)의 초기 단계 <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">암 치료 프로그램을 25억 달러에 인수</a>했다.</li>
<li>브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)와 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 마찬가지로, 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)는 <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">150억 달러 거래로</a> 신경정신적 포트폴리오를 강화하려고 합니다.</li>
<li>크라운 래버러토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)는 레반스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>)의 모든 미상환 보통주를 주당 3.10달러에 인수하겠다고 제안했다.</li>
<li>셀러리어스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)는 디코이 테라퓨틱스(Decoy Therapeutics)와의 거래를 체결했다. 이 회사는 펩타이드 접합 치료제에 초점을 맞춘 초기 단계 생명공학 회사이다. 통합된 개체는 호흡기 질환과 위장관 종양학의 미충족 요구 사항을 목표로 할 것이다.</li>
<li>란테우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)는 <a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging">3억 5천만 달러에 라이프 몰레큘러 이미징을 인수하여</a> 방사선 치료제 분야에서의 입지를 강화했다.</li>
<li> </li>
</ul>
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-td-%EC%9D%80%ED%96%89%EC%9D%B4-%EC%B0%B0%EC%8A%A4-%EC%8A%88%EC%99%91-%EC%A7%80%EB%B6%84%EC%9D%84-%ED%8C%90%EB%A7%A4%ED%95%A0%EA%B9%8C-%EC%95%84/" target="_blank" rel="noopener">여기를 클릭하세요</a><a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">.</a>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">엑센트릭한 억만장자, 전설적인 영화 제작자 하워드 휴즈의 전 마이애미 저택이 5천 550만 달러에 매물로 나왔습니다.</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Ingevity

뉴스

에 대한 최신 뉴스 Ingevity (NYSE:NGVT) 주식

일요일, 1월 19, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌